Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy

Valsartan/sacubitril is a new agent approved for the treatment of chronic heart failure in adults, with a combination of angiotensin receptor inhibitor and neprilysin inhibitor. However, the benefit of valsartan/sacubitril in pediatric patients is unknown. We herein report its clinical benefit in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Shih-Hsing, Liu, Yi-Ching, Dai, Zen-Kong, Chen, I-Chen, Wu, Yen-Hsien, Hsu, Jong-Hau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959725/
https://www.ncbi.nlm.nih.gov/pubmed/33732669
http://dx.doi.org/10.3389/fped.2021.639551
_version_ 1783665012099776512
author Lo, Shih-Hsing
Liu, Yi-Ching
Dai, Zen-Kong
Chen, I-Chen
Wu, Yen-Hsien
Hsu, Jong-Hau
author_facet Lo, Shih-Hsing
Liu, Yi-Ching
Dai, Zen-Kong
Chen, I-Chen
Wu, Yen-Hsien
Hsu, Jong-Hau
author_sort Lo, Shih-Hsing
collection PubMed
description Valsartan/sacubitril is a new agent approved for the treatment of chronic heart failure in adults, with a combination of angiotensin receptor inhibitor and neprilysin inhibitor. However, the benefit of valsartan/sacubitril in pediatric patients is unknown. We herein report its clinical benefit in a case of acute decompensated heart failure in chemotherapy-induced cardiomyopathy. This case suggests that in children with acute heart failure refractory to conventional medications, low dose of sacubitril/valsartan may be an effective therapy.
format Online
Article
Text
id pubmed-7959725
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79597252021-03-16 Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy Lo, Shih-Hsing Liu, Yi-Ching Dai, Zen-Kong Chen, I-Chen Wu, Yen-Hsien Hsu, Jong-Hau Front Pediatr Pediatrics Valsartan/sacubitril is a new agent approved for the treatment of chronic heart failure in adults, with a combination of angiotensin receptor inhibitor and neprilysin inhibitor. However, the benefit of valsartan/sacubitril in pediatric patients is unknown. We herein report its clinical benefit in a case of acute decompensated heart failure in chemotherapy-induced cardiomyopathy. This case suggests that in children with acute heart failure refractory to conventional medications, low dose of sacubitril/valsartan may be an effective therapy. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7959725/ /pubmed/33732669 http://dx.doi.org/10.3389/fped.2021.639551 Text en Copyright © 2021 Lo, Liu, Dai, Chen, Wu and Hsu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Lo, Shih-Hsing
Liu, Yi-Ching
Dai, Zen-Kong
Chen, I-Chen
Wu, Yen-Hsien
Hsu, Jong-Hau
Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
title Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
title_full Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
title_fullStr Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
title_full_unstemmed Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
title_short Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
title_sort case report: low dose of valsartan/sacubitril leads to successful reversal of acute heart failure in chemotherapy-induced cardiomyopathy
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959725/
https://www.ncbi.nlm.nih.gov/pubmed/33732669
http://dx.doi.org/10.3389/fped.2021.639551
work_keys_str_mv AT loshihhsing casereportlowdoseofvalsartansacubitrilleadstosuccessfulreversalofacuteheartfailureinchemotherapyinducedcardiomyopathy
AT liuyiching casereportlowdoseofvalsartansacubitrilleadstosuccessfulreversalofacuteheartfailureinchemotherapyinducedcardiomyopathy
AT daizenkong casereportlowdoseofvalsartansacubitrilleadstosuccessfulreversalofacuteheartfailureinchemotherapyinducedcardiomyopathy
AT chenichen casereportlowdoseofvalsartansacubitrilleadstosuccessfulreversalofacuteheartfailureinchemotherapyinducedcardiomyopathy
AT wuyenhsien casereportlowdoseofvalsartansacubitrilleadstosuccessfulreversalofacuteheartfailureinchemotherapyinducedcardiomyopathy
AT hsujonghau casereportlowdoseofvalsartansacubitrilleadstosuccessfulreversalofacuteheartfailureinchemotherapyinducedcardiomyopathy

Ejemplares similares